Previous Close | 0.8000 |
Open | 0.9700 |
Bid | 0.8300 |
Ask | 0.9200 |
Strike | 50.00 |
Expire Date | 2025-01-17 |
Day's Range | 0.9000 - 0.9700 |
Contract Range | N/A |
Volume | |
Open Interest | 6.33k |
PRINCETON, N.J., June 03, 2024--Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations...
PRINCETON, N.J., June 01, 2024--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced....
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.